echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Hepatitis "drug king" market value of more than 120 billion! Take down the famous chinese medicine side to my colleagues.

    Hepatitis "drug king" market value of more than 120 billion! Take down the famous chinese medicine side to my colleagues.

    • Last Update: 2020-08-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the news that the film to the Longyu Pharmaceutical Industry to invest in holding the news has attracted the attention of the industry, has been the title of the hepatitis "drug king" occupied the high level of the retail market, although the price of raw materials on the product round to increase prices, still can not stop its performance all the way up.
    the outbreak, the company bucked the trend, with a half-year net profit of 860 million yuan, the latest market value has exceeded 120 billion yuan, up more than 87% so far this year.
    Fact, in the face of the ever-changing market environment, the film is constantly changing, in the smooth win the Angong cattle yellow pills, West yellow pills and other classic names, anti-tumor class 1 new drugs are also coming ... Under the outbreak of strong ability to resist pressure, the performance of the tablets do not drop anti-rise table 1: part of the performance of the old Chinese medicine listed companies (units: 100 million yuan) Note: market value statistics as of August 5, 2020 morning close in the first quarter of 2020, by The impact of the new crown epidemic, more than 50% of the listed pharmaceutical enterprises performance (revenue, net profit) double decline, Yunnan White Medicine, Tongrentang, Chip Aberdeen, Dong A gum these old Chinese medicine listed pharmaceutical enterprises as the industry benchmark, performance has attracted much attention.
    yunnan white medicine, the first quarter revenue growth rate of 10.53 percent, 15.51 percent, respectively, in sharp contrast, Tongrentang, Dong A gum decline significantly.
    net profit, the big four listed pharmaceutical companies have only positive growth.
    In the first half of 2020, Dong'a gum is expected to lose 67.54 million to 98.41 million yuan, the company said affected by the domestic epidemic, the first quarter of the domestic part of the dealer resumption of production delayed, and pharmacies and other sales places generally customer flow seriously depressed, resulting in the company's offline business was greatly affected.
    , the company is cleaning up channel inventory, actively strictly control delivery, comprehensive compression of channel inventory quantity, the future will comprehensively promote channel optimization, the establishment of a consumer-oriented operating system.
    's brilliant performance was not affected, the first half of 2020 operating income, net profit both maintained more than 10% growth, net profit for the first time exceeded 800 million yuan, the company's core products, as well as holding subsidiaries of e-commerce and cosmetics sales growth, driving the simultaneous rise in operating profits, as of August 5, 2020, the company's market value of 123.1 billion yuan, up 87.08 percent so far this year.
    hepatitis "drug king" price increases and increases, three exclusive products dominate the retail market Zhangzhou tablets in June 2003 landed on the A-share, in 2006 by the Ministry of Commerce identified as one of the first batch of old Chinese enterprises.
    In the price adjustment announcement issued on March 1, 2005, the domestic sales price of the tablets was raised from 125 yuan/grain to 130 yuan/grain, and the last price adjustment announcement was issued on January 21, 2020, the retail price of the domestic market for tablets was raised from 530 yuan/grain to 590 yuan/grain, and the overseas market supply price was raised by about 5.80 dollars/grain accordingly.
    15 years, the price of the film, 16 times, of which the domestic price adjustment 11 times, the reason for the price adjustment is mostly raw material prices.
    Despite the "rising voice" constantly, but the needs and support of patients is still not reduced, Minet data show that in China's urban retail pharmacies in the market for hepatitis drugs, the market share of the pharmaceutical industry in Zhangzhou, more than 41% in 2019, with the second-place sunflower pharmaceutical industry opened a large gap.
    Figure 1: China's urban retail pharmacies in traditional chinese hepatitis drug TOP3 enterprise market share source: Minet China's urban retail pharmacy pattern Table 2: China's urban retail pharmacies in traditional hepatitis drug brand ranking TOP10 Source: Miannet China's urban retail pharmacy pattern TOP10 brand Among them, the three exclusive products of Zhangzhou Python Pharmaceuticals are on the list, with total sales rising from nearly 500 million yuan in 2015 to more than 800 million yuan in 2019, with a compound annual growth rate of about 12% in 2015-2019.
    the company's main products have the effect of detoxifying heat, cold hemorrhoids, anti-swelling pain relief, used for hot toxic blood clots caused by acute and chronic viral hepatitis, anthraxsores, nameless swelling, fall damage and various inflammation.
    In March 2020, Zhangzhou Python Pharmaceuticals announced that the supplementary application for drug registration submitted for the treatment of primary liver cancer in the middle and late stages of the increase was reviewed and accepted by the State Drug Administration, and the MED China Drug Review Database 2.0 data show that the acceptance number is currently under review and approval, if the new adaptive disease is successfully approved, the product is expected to bring new increments.
    2: The timeline source of the new adaptive review of the film: MED China Drug Review Database 2.0 data listed for the first time in 17 years extended mergers and acquisitions, against Beijing Tongrentang? Behind the brilliant performance of a unique product, the film also felt the pressure of the mountain, and constantly seeking transformation.
    2014, the company began to implement the "one core two wings" development strategy, on the basis of solid pharmaceutical manufacturing industry, strengthen cosmetics, daily chemical products and health care products, health food wings, and at the same time expand the pharmaceutical business sector.
    Table 3: First quarter of 2020 the performance of the various business sectors (units: 100 million yuan) Source: The company announced that according to the first quarter of 2020, the main operating data announcement released by Zhangzhou Phai Pharmaceuticals showed that the pharmaceutical industry revenue increased by nearly 20% Year-on-year, daily necessities, cosmetics sector revenue also broke 200 million yuan, growth rate of nearly 40%, although the food sector revenue is small, but the growth rate is amazing, reaching 48.37 percent.
    On July 25th and 27th, the company issued two announcements in succession, saying that it would invest 44.4759 million yuan in its own funds to invest in Longyu Pharmaceuticals, and obtain a 51% stake in Longyu Pharmaceuticals, which is understood to have completed the equity changes.
    this is the first time in the 17 years since the listing of Zhangzhou's Python Pharmaceuticals that an extended industrial merger and acquisition has been implemented, with the aim of adding code to the main industry and improving the industrial layout.
    industry analysts said that the acquisition of long-term medicine will directly access a number of classic Traditional Chinese medicine, is expected to ease the company's long-term dependence on liver disease drugs.
    supplementary announcement mentioned that, in addition to the dragonfly pharmaceutical industry has an exclusive variety of tortoises to supplement the kidney oral liquid, there are Angong cattle yellow pills (double natural rules), West yellow pills (double natural rules), deer tire paste and other traditional Chinese medicine, with a high market value.
    In the influence of national policies, can use natural cattle yellow, natural musk production of drugs, the number of enterprises, although in recent years, raw materials continue to rise in price, but still do not reduce the patient's pursuit of dual natural products, related enterprises such as Beijing Tongrentang, the film, such as the increase in prices.
    also told the media that after the acquisition will focus on the development of Angong cattle yellow pills and Xi Huang pills two drugs, is expected to become the second series of hepatitis medicine after the two sharp weapons.
    Table 4: 2019 Top3 Angong Bull Yellow Pill, the best-selling brand of China's urban retail pharmacies, is a heavyweight drug in cerebrovascular diseases, and data from Minet.com show that in 2019, the total sales of Angong bull yellow pills in China's urban retail pharmacies exceeded 2.4 billion yuan, of which Beijing Tongrentang and its subsidiaries together accounted for 1.8 billion yuan, with a market share of up to 75%, ranking third among the best-selling brands in China's urban retail pharmacies in 2019.
    West Yellow Pill is used for anthraxtoxic, , flow injection, cancer, etc., the product in China's urban retail pharmacy terminal sales of more than 60 million yuan, Beijing Tongrentang and subsidiaries of the total market share of 70%.
    Table 5: The new drug declaration source: MED China Drug Review Database 2.0 in addition to the extension of mergers and acquisitions, there are new breakthroughs in the research and development of new products: in November 2018, Ma Qianzi total alkali vesicle gel 5 new drugs clinical application was successfully approved, the product is intended to be used for knee osteoarthritis cold blocking evidence caused by pain swelling and other symptoms.
    it is understood that the project adaptation is located in the knee osteoarthritis (cold vein evidence), the current knee osteoarthritis external preparations are mainly mesin gel, sodium bichlorophenol cream, aphrasic ointment, thousand Mountain live blood paste and other drugs, the market is not the same adaptation and the same dosage form of Chinese medicine products on the market, the product uses new technology, local epiderm administration so that the drug in the lesions to form a reservoir and slow release, the effect of arthritis quickly and lasting.
    The company issued a notice on July 7, 2020, the company's PZH2111 new drug clinical trial application by the State Drug Administration review and acceptance, the product is the company's independent intellectual property rights of chemicals class 1 innovative drugs, mainly used for the treatment of liver bile tube cell carcinoma, urethra cell carcinoma and other advanced physical tumors, domestic no similar drugs with the same adaptation has been approved for listing.
    data source: China's urban retail pharmacies in the traditional drug terminal competition pattern original title: hepatitis "drug king" market value of more than 120 billion! Take down the famous Chinese medicine side to the tongrentang, a class of new drug sword refers to tumors.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.